Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1736

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1736
---
 Cost of Revenues 
     384,765  
     474,550 
  
    Gross Profit (Loss) 
     222,809  
     (220,977)
  
    Research Revenues 
     73,771  
     - 
  
    Net Revenue (Loss) 
     296,580  
     (220,977)

    Operating Expenses: 

    Research and Development 
     4,986,526  
     691,770 
  
    General and Administrative Expenses 
     5,024,985  
     4,241,836 
  
    Total Operating Expenses 
     10,011,511  
     4,933,606 

    Loss from Operations 
     (9,714,931) 
     (5,154,583)

    Interest Expense 
     (7,912) 
     (2,286,637)
  
    Derivative Expense 
     -  
     (399,725)
  
    Change in Fair Value of Derivative Liabilities 
     1,665,966  
     (37,278)
  
    Loss on Debt Extinguishment 
     -  
     (1,231,480)
  
    Change in Fair Value of Promissory Note 
     -  
     5,379,269 
  
    Other Income (Expense), net 
     101,464  
     (83,116)
  
    Total Interest and Other Income (Expense), net 
     1,759,518  
     1,341,033 
  
    Loss from Operations before Provision for Income Taxes 
     (7,955,413) 
     (3,813,550)
  
    Provision for Income Taxes (Note 9) 
     250  
     250 
  
    Net Loss including Noncontrolling Interest 
     (7,955,663) 
     (3,813,800)
  
    Net Loss – Noncontrolling Interest 
     (8,556) 
     (48,098)
  
    Net Loss – attributed to 60 Degrees Pharmaceuticals, Inc. 
     (7,947,107) 
     (3,765,702)

    Comprehensive Loss: 

    Net Loss 
     (7,955,663) 
     (3,813,